Podcasts about Pharma

"Case Closed: Lee Harvey Oswald and the Assassination of JFK" was first published in 1993."Killing the Dream : James Earl Ray and the Assassination of Martin Luther King, Jr." was first published in 1998.You can hear Michael's other book interviews with Gerald Posner in Episodes #214 (God's Bankers), #222 (Pharma), #285 (Case Closed). Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Episode 5 of Standard Deviation with Oliver Bogler on the Out of Patients podcast feed pulls you straight into the story of Dr Ethan Moitra, a psychologist who fights for LGBTQ mental health while the system throws every obstacle it can find at him.Ethan built a study that tracked how COVID 19 tore through an already vulnerable community. He secured an NIH grant. He built a team. He reached 180 participants. Then he opened an email on a Saturday and learned that Washington had erased his work with one sentence about taxpayer priorities. The funding vanished. The timeline collapsed. His team scattered. Participants who trusted him sat in limbo.A federal court eventually forced the government to reinstate the grant, but the damage stayed baked into the process. Ethan had to push through months of paperwork while his university kept the original deadline as if the shutdown had not happened. The system handed him a win that felt like a warning.I brought Ethan on because his story shows how politics reaches into science and punishes the people who serve communities already carrying too much trauma. His honesty lands hard because he names the fear now spreading across academia and how young scientists question whether they can afford to care about the wrong population.You will hear what this ordeal did to him, what it cost his team, and why he refuses to walk away.RELATED LINKSFaculty PageNIH Grant DetailsScientific PresentationBoston Globe CoverageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Not gonna give much of an introduction here because this is a short bonus level set, but I did just wanna call everyone's attention to the "arms race" created by our status quo purchasing and selling of many things, pharmaceuticals included. For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. For example, raise the list price of a drug to maximize rebates, because the higher the list, the bigger the discount you can give, which then exacerbates patient affordability because coinsurance is often based on list price. But then Pharma starts offering co-pay cards, which messes up the whole PBM (pharmacy benefit manager) plan to drive patients to their highest-rebate products (ie, the most profitable products). So then maximizers and accumulators enter the chat, and prior auths ramp up because plans start having to raise premiums after enough 340B drugs with high lists and no rebates, and then there's no cost containment and raise deductibles and around and around we go. Meanwhile, is this drug fundamentally worth the list price or even the net price? Is it an effective drug? What's the right price to be paying for this drug? Should be the operative question, right? Just like what's the quality and appropriateness of any medical service? Maybe we should just quit it and just pay for value. And with that, let me introduce Sarah Emond, CEO of ICER (Institute for Clinical and Economic Review), and I will let Sarah tell the rest of the story. Also mentioned in this episode are Institute for Clinical and Economic Review (ICER); Cora Opsahl; 32 BJ Health Fund; Payerset; Aventria Health Group; Dea Belazi, PharmD, MPH; and Tom Nash. For a list of healthcare industry acronyms and terms that may be unfamiliar to you, click here.   You can learn more at ICER.org and follow Sarah on LinkedIn.   Sarah K. Emond, MPP, is president and chief executive officer of the Institute for Clinical and Economic Review (ICER), a leading nonprofit health policy research organization, with 25 years of experience in the business and policy of healthcare. She joined ICER in 2009 as its first chief operating officer and third employee and has worked to grow the organization's approach, scope, and impact over the years. Prior to joining ICER, Sarah spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company and several years with a healthcare communications firm. Sarah began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston. A graduate of the Heller School for Social Policy and Management at Brandeis University, Sarah holds a Master of Public Policy degree with a concentration in health policy. Sarah also received a bachelor's degree in biological sciences from Smith College. Sarah speaks frequently at national conferences on the topics of prescription drug pricing policy, comparative effectiveness research, and value-based healthcare.   02:28 What is ICER? 02:47 What does the Institute for Clinical and Economic Review do? 05:09 The importance of still showing up, even when others don't understand or disagree. 06:51 EP293 ("Game Theory Gone Wild") with Dea Belazi, PharmD, MPH. 09:04 Why it's important to think about population health and how our choices impact affordability for everyone.   You can learn more at ICER.org and follow Sarah on LinkedIn.   @sarahkemond discusses #ICER and the status quo of #pharmaceuticaldrug #pricing on our #healthcarepodcast. #healthcare #podcast #financialhealth #patientoutcomes #primarycare #digitalhealth #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Stacey Richter (INBW43), Olivia Ross (Take Two: EP240), John Quinn, Dr Sam Flanders and Shane Cerone (EP492), Elizabeth Mitchell (EP491), Shane Cerone and Dr Sam Flanders (Part 1), Dan Greenleaf (Part 2), Dan Greenleaf (Part 1), Mark Cuban and Cora Opsahl  

I was out drinking martinis with Cora Opsahl, director of 32BJ Health Fund, and Cora said, "Look, most plan sponsors' biggest expense is health system spend, hospital spend." I know this is an unexpected start to an episode about pharmaceutical pricing and value featuring Sarah Emond, CEO of ICER (Institute for Clinical and Economic Review). But yeah, 50% of most plan sponsors' spend these days goes to health systems. Fifty percent! One half! For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. So, if a patient who is adherent to a drug and that drug keeps that patient out of the hospital, why do I want to make a patient have excessive skin in the game to get that drug, which everybody knows at this point this "skin in the game" can cause said patient to not be adherent in many cases, cost being a very big reason patients give for not taking medications as prescribed. So then we have this not adherent patient who winds up in the hospital, via the ER often enough. The core issue here that surfaced, bottom line—and I'm not sure if this was in spite of the martinis or as a result of them—but while hospital spend is the largest health expense, high-value drugs that prevent hospitalization often face patient cost sharing and access restrictions, which leads to poor patient adherence and ultimately higher system cost potentially. So then Cora and I spent the next half hour debating when the statement is empirically true and when it's not. And you know what it all boils down to? What's the value of the drug? Do we even know what that means to start? But if it's determined that the drug is relatively high value, then the plan desperately should want to do everything possible to keep that patient on that medication, and cost sharing is a huge barrier to adherence. Today, as I said, I'm speaking with Sarah Emond, CEO over at ICER, and we get into all of this in the conversation that follows. In fact, most of the conversation that follows explores the tensions that exist in the current way that we sell and buy pharmaceutical products. I'm just gonna sum up these tensions in a list here at the top of this show. There's six of them that Sarah Emond and I discussed today by my counting, and each of these we explore in some depth. So, here's the list. Tension 1: The value of any given drug (in other words, what is the fair price for that drug considering the health gains that it delivers) versus the total cost to the plan for the total population taking that drug. GLP-1s have entered the chat. GLP-1s (by ICER's analysis, at least) are super high-value drugs that also can bankrupt plans due to the number of folks who may benefit from taking the drug. Definitely a tense tension to kick off our list here. Tension 2: The list or net price of a drug versus patient access and affordability. Again, this can be tense in an area of much misalignment. You can have a great well-priced drug with huge patient affordability and access challenges because drug net price and coinsurance amounts often have nothing to do with each other. Tension 3: Lifetime value of a drug versus a 3-, 2.5-year, whatever time horizon that many plan sponsor actuaries use in their value assessment. We discussed this today, but there's a Summer Short (SUMS7) on actuarial value horizons with Keith Passwater and JR Clark if you wanna dig in on this further. Tension 4: The tension between the societal value of a drug or even the patient's perceived value of a drug versus what an employer plan sponsor might perceive as the value. What is the formula used to determine value? What's in and what's out? So, that's a bigger conversation just beyond the time horizon for what's included in this calculation. Tension 5: Exacerbating the what's included in the value contemplation beyond just what you include in there is the tension between what is hypothetically of value and what is possible to measure. If you have pharma datasets and medical datasets separate in silos, who knows how many hospital readmissions were prevented by whatever drug? And how much presenteeism or absenteeism exists. I mean, it is an outlier, again, if anyone even knows the net price they paid for a drug, just to level set context here. Tension 6: Lowering financial barriers for patients to take drugs that are of value versus status quo goals and incentives. Like, for example, PBMs (pharmacy benefit managers) are often told that their goal is to reduce drug spend. Okay … so, how do I do that? Oh, reduce access either by prior auths or delay tactics or really high coinsurance, which is gonna reduce adherence by design. And it's someone else's problem—if I'm just thinking like a status quo PBM—if medical spend goes up, right? So, that's our last and not insignificant tension. And look, who comes out the loser in all of these tensions when they get tense? Patients. Not pricing based on value and not buying and setting up cost sharing based on value punishes patients and also plan sponsors or any other ultimate purchaser in the long term, given that the plan is but a population of patients if you start thinking about it in that context. Here is Sarah's advice in a nutshell: Pharma, sell. Pick your price based on something other than market power. And some pharma companies are actually dipping their toe into these waters and doing it. But then PBMs and plan sponsors have to hold up their end of the bargain here and buy drugs based on their value, not just the size of their rebates or some other discounting promise. And then we gotta continue the through line through to member affordability and access. High-value drugs should get preferred. So, right, do a high-value formulary. Listen to the show with Nina Lathia, RPh, MSc, PhD (EP426) on high-value formularies and then listen (after you're done with that one) to episode 435 with Dan Mendelson entitled "Optimized Pharmacy Benefits Are Required if You Want to Do or Buy Value-Based Care." Also, as I said, GLP-1s come up in this conversation, so … yeah, buckle up. One last thing, besides my normal thank you to Aventria Health Group for sponsoring this episode, I am so pleased to thank Payerset for donating to help Relentless Health Value stay on the air. Payerset is a price transparency company with a mission to create fair and equitable healthcare for everyone. Love that. Payerset empowers healthcare organizations, employers, and patients with the most complete set of healthcare price transparency data. They benchmark every negotiated rate and claim and delivering the actionable insights needed for smarter contract negotiations and a more transparent healthcare system. As I have said several times today, my conversation is with Sarah Emond, CEO of ICER. Also mentioned in this episode are Institute for Clinical and Economic Review (ICER); Cora Opsahl; 32 BJ Health Fund; Keith Passwater; JR Clark; Nina Lathia, RPh, MSc, PhD; Dan Mendelson; Aventria Health Group; Payerset; Antonio Ciaccia; Elizabeth Mitchell; Purchaser Business Group on Health (PBGH); Shane Cerone; Sam Flanders, MD; Mark Cuban; Morgan Health; and Tom Nash. For a list of healthcare industry acronyms and terms that may be unfamiliar to you, click here. You can learn more at ICER.org and follow Sarah on LinkedIn.   Sarah K. Emond, MPP, is president and chief executive officer of the Institute for Clinical and Economic Review (ICER), a leading nonprofit health policy research organization, with 25 years of experience in the business and policy of healthcare. She joined ICER in 2009 as its first chief operating officer and third employee and has worked to grow the organization's approach, scope, and impact over the years. Prior to joining ICER, Sarah spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company and several years with a healthcare communications firm. Sarah began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston. A graduate of the Heller School for Social Policy and Management at Brandeis University, Sarah holds a Master of Public Policy degree with a concentration in health policy. Sarah also received a bachelor's degree in biological sciences from Smith College. Sarah speaks frequently at national conferences on the topics of prescription drug pricing policy, comparative effectiveness research, and value-based healthcare.   08:18 Why list prices are a lie. 10:59 How does the rebate model sometimes get in the way of paying for value? 12:50 Bonus clip with Sarah Emond. 13:14 EP491 with Elizabeth Mitchell. 13:20 EP490 and EP492 with Shane Cerone and Sam Flanders, MD. 14:37 The tension that is created between affordability and adherence. 15:03 When cost sharing makes sense in pharmaceutical drug pricing. 17:26 INBW42 with Stacey on moral hazard. 18:53 How GLP-1s are "wildly cost effective." 21:32 Why the sticker shock on cost-effective drugs is a failure in the system for paying for value. 22:38 ICER's report on GLP-1s. 26:59 EP385 with Dan Mendelson. 28:57 How employers and payers can have a value assessment approach and a health insurance system that allows access to cost-effective drugs. 29:48 How cost-effective prices are calculated. 31:55 One of the core value underpinnings for value assessment of drugs. 34:54 Why manufacturers and pharmacy benefit managers should work together more by referencing something like an ICER report. 36:55 EP426 with Nina Lathia, RPh, MSc, PhD. 38:21 "We can make different choices."   You can learn more at ICER.org and follow Sarah on LinkedIn.   @sarahkemond discusses #pharmaceutical #drugpricing on our #healthcarepodcast. #healthcare #podcast #financialhealth #patientoutcomes #primarycare #digitalhealth #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Stacey Richter (INBW43), Olivia Ross (Take Two: EP240), John Quinn, Dr Sam Flanders and Shane Cerone (EP492), Elizabeth Mitchell (EP491), Shane Cerone and Dr Sam Flanders (Part 1), Dan Greenleaf (Part 2), Dan Greenleaf (Part 1), Mark Cuban and Cora Opsahl

Big tech is stumbling while pharma stocks surge, what does that mean for markets heading into 2026? In this episode, Anthony and Piers unpack why Nvidia, Microsoft, and Amazon are dragging, while Eli Lilly and Merck lead a surprising rotation. They also explore shifting Fed rate cut expectations, conflicting US labor data, and what it all signals for the S&P 500's next move.We also break down Deutsche Bank's “triple whammy” dollar call, Trump's Fed chair pick, and why a yen carry trade unwind could shake crypto markets. Plus, UK PMI surprises and pound strength, are brighter days ahead for the UK economy? Tune in for easy-to-follow macro insights this week!(00:00) Topics & Listener Shoutouts(02:51) Big Tech Wobble, Pharma Surge(09:16) Fed Cut Expectations & Labour Data(18:27) Trump's Fed Pick & Market Reaction(24:23) Deutsche Bank US Dollar Call(30:07) Yen Carry Trade & Crypto Risk(36:01) UK Budget Bounce & PMI Surprise*****Last chance to join our in-person Finance Bootcamp in London 15-19 December 2025. As part of our podcast community, you can use the code BOOT500 at checkout for a £500 discount.

Why is the NHS paying more for new medicines? Will the government at last buy from British tech companies? How can the UK life sciences be more entrepreneurial? Lord Patrick Vallance, the government's Science, Innovation Research & Nuclear Minister (and former Chief Scientific Advisor), joins Robert and Steph to talk about trade deals, scale-up finance and how investing in the Oxford-Cambridge corridor might mean growth for the whole country. Visit: https://www.gov.uk/teachinfurthereducation to find out more. Download the app to experience Blacklane yourself: https://blacklane.onelink.me/PVgS/pa5yx0q7 Email: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠restismoney@gmail.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ X: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@TheRestIsMoney⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@TheRestIsMoney⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ TikTok: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@RestIsMoney⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://⁠⁠⁠goalhanger.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit podcastchoices.com/adchoices

In den Kommentaren geht es unter anderem um den Pharma- und Agrarchemiekonzern Bayer. www.deutschlandfunk.de, Wirtschaftspresseschau

Pharma deal, Supreme Court on piracy, special election in Nashville, and a TSA record. Plus, the Message of the Day, on heaven and hell… Learn more about your ad choices. Visit megaphone.fm/adchoices

Chelsea J. Smith walks into a studio and suddenly I feel like a smurf. She's six-foot-three of sharp humor, dancer's poise, and radioactive charm. A working actor and thyroid cancer survivor, Chelsea is the kind of guest who laughs while dropping truth bombs about what it means to be told you're “lucky” to have the “good cancer.” We talk about turning trauma into art, how Shakespeare saved her sanity during the pandemic, and why bartending might be the best acting class money can't buy. She drops the polite bullshit, dismantles survivor guilt with punchline precision, and reminds every listener that grace and rage can live in the same body. If you've ever been told to “walk it off” while your body betrayed you, this one hits close.RELATED LINKS• Chelsea J. Smith Website• Chelsea on Instagram• Chelsea on Backstage• Chelsea on YouTube• Cancer Hope Network• Artichokes and Grace – Book by Chelsea's motherFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore the latest advances and strategic moves shaping the industry, providing you with insights into how these developments might influence drug development and patient care.The pharmaceutical and biotech sectors are currently experiencing a wave of transformative changes. A significant development is the trade agreement between the United States and the United Kingdom, which excludes medicines from import tariffs. This strategic move, orchestrated by the Trump administration, is set to reduce costs and bolster investments in pharma sectors across both nations. By enhancing market accessibility, it aims to stimulate cross-border investment in pharmaceutical research and production.On the clinical front, Eli Lilly is making headlines by joining Novo Nordisk in reducing self-pay prices for its GLP-1 receptor agonist, Zepbound. This reflects a broader industry trend towards patient-centric pricing models aimed at improving affordability. With healthcare costs on the rise, these measures could ease financial burdens for patients requiring long-term medication regimens.Regulatory updates are also making waves, with the FDA planning stricter vaccine regulations under Dr. Vinay Prasad's leadership at the Center for Biologics Evaluation and Research (CBER). These updates come amid concerns over vaccine safety during COVID-19-related incidents, underscoring a commitment to maintaining public trust in vaccines. Regulatory scrutiny continues as Prasad focuses on COVID-19 vaccine safety in children amid reports linking 10 child deaths to vaccines via VAERS—emphasizing challenges interpreting safety data while highlighting the need for robust methodologies ensuring reliable causality conclusions.In corporate restructuring news, Valneva is streamlining its operations by closing a site and eliminating 30 roles. This move highlights an industry focus on optimizing resources to bolster vaccine development pipelines. Meanwhile, Microsize and Schedio's acquisition of Lonza's Swiss micronization plant underscores ongoing investments in advanced manufacturing technologies critical for high-quality pharmaceuticals.In ophthalmology, Belite Bio is advancing with promising Phase 3 results for tinlarebant in treating Stargardt disease—a rare genetic eye disorder. This success positions Belite to file for FDA approval, potentially expanding treatment options for this underserved patient population. Such advancements in targeted therapies emphasize the need for ongoing research in genetic disorders.Regeneron is betting $150 million on Tessera's gene writing technology targeting alpha-1 antitrypsin deficiency (AATD). This collaboration highlights the industry's growing interest in gene therapy as a frontier for treating rare diseases, marking a shift towards precision medicine where tailored genetic interventions offer hope for previously untreatable conditions. Regeneron's strategic move investing $275 million partnering with Tessera exploring gene editing capabilities—focusing on TSRA-196 targeting the SERPINA1 gene linked to AATD showcases potential advancing therapeutic options for genetic disorders through gene editing technologies offering new disease treatment avenues.AI-driven platforms were spotlighted at RSNA 2025 by industry leaders such as GE Healthcare, Philips, and Siemens. These innovations promise to revolutionize radiological workflows by enhancing diagnostic accuracy and operational efficiency through AI integration. As AI continues to permeate healthcare technologies, its potential to transform diagnostic processes marks a significant leap towards personalized medicine.Akebia Therapeutics' acquisition ofSupport the show

ImmuPharma PLC (AIM:IMM) CEO Tim McCarthy talked with Proactive's Stephen Gunnion about the company's ongoing discussions to secure a partnership for its lead asset, P140. McCarthy addressed investor concerns following a recent update that indicated the timing of a potential deal may now move into 2026. He explained that while the company had initially targeted the end of 2025 for deal completion, the timeline adjustment reflects strong ongoing engagement with multiple pharmaceutical companies—some of which include top ten global players. “We were all very pleasantly surprised [by] the amount of interest and positive interest from the pharma companies,” McCarthy stated. The discussions follow the September filing of a new patent for P140, which was based on a “groundbreaking discovery” made by the company's scientific team. McCarthy emphasised that the scientific and commercial value of P140 remains unchanged, and that the company is focused on finding the right partner and structure for shareholders. He also provided reassurance regarding ImmuPharma's financial position. Recent R&D tax credits, exercised warrants, and completion of a Lanstead share agreement have extended the company's cash runway well into Q4 2026. McCarthy confirmed there is “no intention at all” to raise new funds via the market. For more interviews like this, visit Proactive's YouTube channel. Don't forget to like the video, subscribe to the channel, and enable notifications for future content. #ImmuPharma #P140 #BiotechNews #PharmaDeals #DrugDevelopment #TimMcCarthy #BiotechInvesting #LupusTreatment #Pharmaceuticals #ClinicalResearch #StockMarketNews #InvestorUpdates

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce that the company has formally submitted an FDA Commissioner's National Priority Voucher (CNPV) application on behalf of its partner SkinJect, seeking expedited regulatory review for the Doxorubicin Microneedle Array (D-MNA) a novel, non-invasive treatment for basal cell carcinoma (BCC) of the skin. The submission includes a detailed Statement of Interest setting out how SkinJect aligns with the FDA's highest national priorities, including improved cancer-care accessibility, reduced treatment costs, and the urgent unmet needs in rare diseases such as Gorlin Syndrome, where no approved therapies currently exist. Dr. Bokhari explained that, if granted, the CNPV voucher would allow Medicus and SkinJect to participate in a commissioner-led FDA review process that dramatically reduces regulatory timelines. Under this program, a drug developer's final application could be evaluated in 1–2 months, compared to the traditional 10–12-month review cycle. Unlike the standard review pathway—where an application is routed through multiple FDA divisions—the new CNPV pilot brings together specialists from across the agency into a single cross-functional expert team, enabling faster, more coordinated decision-making. The FDA intends to award only a limited number of vouchers in the program's first year, specifically to products that directly support U.S. national health priorities. In addition to the time-saving benefits, qualifying therapies may also be eligible for accelerated approval, provided they meet applicable legal and clinical criteria. Medicus Pharma believes SkinJect is well positioned for inclusion. The Doxorubicin Microneedle Array offers a localized, cost-effective, and non-surgical alternative to current BCC treatments. Basal cell carcinoma is the most common cancer in the United States, with more than five million new cases annually, representing a substantial public-health burden. The company views the CNPV program as an important opportunity to advance a U.S.-developed cancer therapy that strengthens national goals of accessibility, safety, affordability, and quality of care. Dr. Bokhari emphasized that gaining entry into the pilot would help accelerate the delivery of a much-needed medical innovation to both general BCC patients and underserved rare-disease communities. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #GorlinSyndrome #BasalCellCarcinoma #CompassionateUse #FDAApproval #RareDiseaseTreatment #NoninvasiveTherapy #BiotechNews

Celebrate, The Savior is Here!Jesus Christ is Alive!Get to know Jesus Christ, He will change your life!!!Go to GOD for discernment and wisdom.Know the Truth as the Truth will make you free! (John 8:32)___The Pledge of AllegianceNEO420 = Real News + Real Information for WE THE PEOPLEWE THE PEOPLE are at war with the deepstate criminal cabal!!!Turn off your tv, radio, and stop listening to paid professional liars spreading propaganda.***SUPPORT Independent Free Speech Reporting***Thank you for the SUPPORT & SHARING the TRUTH!!!___Podcast  link is here http://neo420.com/talks-podcast/The video channel link is here. https://odysee.com/@NEO420TALKS:4The Viral Delusionhttp://www.theviraldelusion.com/HAARPDARPA BlackjackAshli Babbit false flag Jan 6 video evidence___NEVER FORGET 9 11!!!Rumsfeld admitted $2.3 Trillion missing from Pentagon Sept 10 2001.  https://odysee.com/@NEO420TALKS:4/rumsfeld-2.1Trillionunaccountedforb-ccriminalsstoleit:7Planes did NOT bring down the two towers.AE911Truth.orgGeorge Bush Sr was CIA director before being Vice President then President.Towers that fell:-Building 1-Building 2-Building 7 (seldom reported even though BBC reporter reported building down before it happened) https://www.youtube.com/watch?v=J0VFMqi--Copyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for "fair use" for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. Fair use is a use permitted by copyright statute that might otherwise be infringing. Non-profit, educational or personal use tips the balance in favor of fair use.Support the show

Weltweit gibt es viele Millionen Menschen, die an chronischen Schmerzen leiden. Allein in Europa gehen die Schätzungen von mehr als 100 Millionen Betroffenen aus. Doch viele Schmerzmittel haben Nebenwirkungen - oder sie machen durch ihre opium-artigen Inhaltsstoffe die Patienten abhängig. Aber es könnte schon absehbar eine Alternative für sie geben - mit deutlich weniger Nebenwirkungen.

✅ Sichere dir jetzt die Schritt-für-Schritt Themenübersicht – Fliegenpilze: Hier klicken✅ Hochwertiges Fliegenpilz-Pulver (100% Naturprodukt & laborgeprüft) hier erhältlich: Hier klicken

In this gripping episode of the Medical Sales Podcast, Samuel sits down with Jennifer Jones, a former top Purdue Pharma rep who lived through one of the most turbulent eras in pharmaceutical history. Jennifer recounts her shocking personal encounters with the FBI, the emotional strain of grand jury testimony, the collapse of Purdue from the inside, and the complicated reality reps faced far beyond the headlines. She shares raw stories of ethical dilemmas, patient advocacy, "pill mill" misconceptions, and the unseen pressures of pain management in the 2000s. Jennifer then opens up about rebuilding her life and identity after Purdue's shutdown, scaling a thriving wine business, launching a coaching company, and ultimately returning to medical device sales where she now leads in cardiology. This conversation delivers rare honesty about pharma, entrepreneurship, career reinvention, and what it truly takes to survive, grow, and lead in medical sales today.   Connect with Jennifer Jones: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How »

Kathryn Golden didn't set out to be a scientist. In fact, she made her parents promise she wouldn't have to become one when she enrolled at a science-focused high school. But a chemistry class changed everything, setting her on a path from MIT's bioprocessing labs to senior leadership roles in Biotech and pharma.  Now VP of Technical Operations at Ottimo Pharma and co-founder of Sunflower Therapeutics, Kathryn's career has been shaped by a relentless curiosity, a deep commitment to patient access, and a willingness to step into the unknown. She shares her journey from building perfusion bioreactors in grad school, to leading global CMC teams, to launching portable manufacturing units for biologics in the developing world.  In this conversation, Kathryn reflects on lessons in leadership, mentorship, and integrity - from creating a calm, learning-focused culture to knowing when to walk away. She talks openly about imposter syndrome, what it really takes to transition into executive roles, and how entrepreneurship, like science, is best approached as an experiment. 

Justin Thomas-Copeland is the CEO of the 4As, but key aspects of his career arc are defined by leadership assignments in the world of healthcare.Before he ascended to the top spot at the ad industry's leading trade association, Justin lived the best of both worlds in healthcare: working brandside and at an agency supporting pharma clients.In the early 2010s, he served as chief digital officer, Europe for Novartis – developing the Swiss drugmaker's first digital strategy. From there, he rejoined the agency world as the managing director and global client lead for Team Novartis at Wunderman EMEA.At the end of the decade, he served as global CEO of OPMG Health at Omnicom Precision Marketing Group.MM+M editor-in-chief Jameson Fleming brings us an extended conversation with Justin about what his early experience as a health leader taught him about advertising and why thinks digital marketing can reimagine health brands.And for our Trends segment, we're talking about Secretary Kennedy's admission that he personally directed the Centers for Disease Control and Prevention to change its guidance on the link between vaccines and autism.  Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

BEST BUDS OR DUDS? - 11.24.2025 - #894 BestPodcastintheMetaverse.com Canary Cry News Talk #894 - 11.24.2025 - Recorded Live to 1s and 0s Deconstructing World Events from a Biblical Worldview Declaring Jesus as Lord amidst the Fifth Generation War! CageRattlerCoffee.com SD/TC email Ike for discount https://CanaryCry.Support   Send address and shirt size updates to canarycrysupplydrop@gmail.com   Join the Canary Cry Roundtable This Episode was Produced By:   Sir Trevor G Knight of the Twisted Pines!   Sir Puer Villachus, the Magyar Viking from the Banks of the Dravus River, Knight of the Squirrel Dogs in frozen lands of the North   Executive Producers LX Protocol BARON of the Berrean Protocol*** Sir Jamey Not the Lanister***   Producers of TREASURE (CanaryCry.Support) Ricky B, Marty K, Kona, Sir Darrin Knight of the Hungry Pandas, Benjamin, Cheryl E, Brandon W, Cage Rattler Coffee    Producers of TIME Timestampers: Jade Bouncerson, Morgan E Clankoniphius Links: JAM   TRUMP 5:23 Clip: Trump meeting with Mamdani (AP) Longer Clip: Trump Mamdani are Best Friends  Clip: Chris Shillzilla Analysis   WORLDCOIN 43:17 Sam Altman's Eyeball-Scanning Orb Startup Made Cult-Like Demand of Employees (Futurism)   COVID, WAXXINATION 1:10:02 UK Gov withholding excess death data (The Telegraph)  7 Days Later, DailyMail announces purchase of Telegraph (DailyMail) DailyMail copy paste - then give the standard defense (DailyMail)   PHARMA 1:33:13 The Rise and Fall of "Ostrich Pharma" (The Atlantic)    EXECUTIVE PRODUCERS 2:26:00 TALENT/TIME 2:53:35 END 3:08:00

When Julia Stalder heard the words ductal carcinoma in situ, she was told she had the “best kind of breast cancer.” Which is like saying you got hit by the nicest bus. Julia's a lawyer turned mediator who now runs DCIS Understood, a new nonprofit born out of her own diagnosis. Instead of panicking and letting the system chew her up, she asked questions the industry would rather avoid. Why do women lose breasts for conditions that may never become invasive? Why is prostate cancer allowed patience while breast cancer gets the knife? We talked about doctors' fear of uncertainty, the epidemic of overtreatment, and what happens when you build a movement while still in the waiting room. Funny, fierce, unfiltered—this one sticks.RELATED LINKS• DCIS Understood• Stalder Mediation• Julia's story in CURE Today• PreludeDx DCISionRT feature• Julia on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episod is brought to you by Cured Nutrition, Caldera Lab and Joi & Blokes. Dr. Jessica Shepherd—OB/GYN, clinical advisor for P-Volv, and author of Generation M—breaks down everything women need to know about perimenopause, menopause, and longevity. She explains why mindset is the foundation of midlife health, how declining estrogen affects every organ system, why only 8% of symptomatic women ever receive a diagnosis, and how common comorbidities rise 45% or more between ages 40–59. Dr. Shepherd shares science-backed strategies for navigating symptoms, improving metabolic and mitochondrial health, understanding the truth about hormone therapy after the flawed WHI study (which led to an 82% decline in prescriptions), and using exercise, protein, and muscle-building to protect cognition, heart health, and overall vitality. Whether you're a woman entering midlife—or a partner wanting to better support her—this conversation is a masterclass in women's health, empowerment, and aging well. Follow Jessica @jessicashepherdmd Follow Chase @chase_chewning ----- 00:01 - Intro & shocking stats: women live longer but spend more years in poor health; HRT prescriptions dropped 82% after 2002 00:28 - Muscle as the organ of longevity; women lose 3–5% per decade, accelerated after menopause 01:18 - Why estrogen decline shifts the whole body; Dr. Shepherd introduces herself and her mission in women's health 02:15 - Redefining women's health & longevity; why women aren't thinking about longevity soon enough 04:23 – Mindset, habits, and community as the foundation of midlife health 07:13 - Barriers to staying well: socioeconomic factors, upbringing, access, and misconceptions about wellness 09:33 - Women's current wellness landscape; societal expectations, caregiving burden, and systemic gaps 12:46 – Major healthcare gaps: lack of research, exclusion of women from clinical studies until the '70s, and only 3% of VC health funding going to women 17:30 – Pharma eliminating women's health divisions; downstream effects on innovation and access 19:10 – Perimenopause 101: defining terms, symptoms vs. cycles, 34+ possible symptoms, and why diagnosis is trick 24:45 – The cardiovascular danger of estrogen decline; heart disease as the #1 killer of women 27:02 – Stress vs. perimenopause symptoms; mood disorders peak between 45–55 29:48 – How HRT has evolved in the last 10–20 years; symptom relief and longevity benefits 32:32 – Why only 5% of women are on hormone therapy today; misconceptions and new guidelines 34:20 – WHI study deep dive: media panic, misinterpretation, lack of statistical significance, and lasting fear 39:06 – Risk vs. benefit: how to think about HRT decisions with your provider 41:51 – Chase shares his TRT story; quality of life, fertility considerations, and hormone literacy 45:16 – Dr. Shepherd's personal hormone story: cognition issues, testosterone, and starting estrogen at 46 48:12 – Supplements Dr. Shepherd uses: Vitamin D, creatine, CoQ10, Urolithin A 50:10 – Muscle, mitochondrial health, sarcopenia & glucose control: why resistance training is non-negotiable 52:25 – Movement, neuroplasticity, balance & cognition: why staying active protects the aging brain 55:12 – How partners can best support women in perimenopause: emotional support & shared routines 57:52 – The science of emotional support: social connection decreases pain, inflammation, and improves outcomes 59:22 – Menopause explained: average age, symptom timeline, and the hidden cellular changes 01:02:39 – Nutrition, glucose control, protein needs, alcohol & sugar intake, and metabolic health 01:07:07 – Protein requirements (1.0–1.2g/kg), resistance training, and why women must build muscle 01:09:37 – U.S. data: 55%+ of women report symptoms; only 8% diagnosed; why doctors miss it 01:12:34 – Which providers are best for menopause care & what certifications to look for 01:15:31 – Comorbidities rise 45% between 40–59: hypertension, thyroid, arthritis, sleep disorders & estrogen's role 01:18:25 – Is biohacking menopause possible? Current limits + ovarian longevity research 01:22:24 – Exercise as the ultimate biohack; sustainable movement for aging wel 01:23:19 – Final Q: How Dr. Shepherd lives Ever Forward — flexibility, pause, and growth ----- Episode resources: 20% off DREAM gummies with code EVERFORWARD at CuredNutrition.com/everforward 50% off any product or diagnostic labs with code CHASE at JoiAndBlokes.com/chase 20% off any men's skincare product with code EVERFORWARD at CalderaLab.com Watch and subscribe on YouTube

In this episode, we explore four transformative topics reshaping how we think about whole-body health:1. The Lasting Impact of Prescription Drugs on Gut HealthFrom antibiotics to acid reducers, we uncover how common medications can shift the delicate microbial balance in ways that influence digestion, metabolism, and even mental well-being.2. MIT's Discovery: An Amino Acid That Helps the Gut Heal ItselfBreakthrough science takes center stage as we examine MIT's recent findings surrounding a specific amino acid shown to support gut barrier integrity. We translate the lab data into real-world insights, exploring how this discovery could inspire future therapies. 3. Superstars for Gut–Brain Axis Health and VitalityMeet the nutrients that support a thriving communication network between your gut and brain. From Wellness Resources we spotlight the “all-stars” that keep your inner ecosystem and emotional wellness in sync. 4. Top 20 Natural Remedies Overlooked by Mainstream MedicineWe explore the history, cultural significance, and research landscape surrounding these natural options and play a clip by Dr. Eric Berg exploring what these remedies are and more importantly what they have been used for.

In this episode (recorded last year), Dr. Sabine Hazan, a gastroenterologist and microbiome researcher, joins the hosts of the BS Free MD Podcast to lay bare what she claims is a systemic problem: the undue influence of large pharmaceutical companies over medical research, regulatory bodies, publication of scientific data, and the shaping of public-health narratives.She describes her own journey during the COVID-19 pandemic: attempting research on treatments (including microbiome related therapies, and alternative protocols) and encountering what she characterizes as institutional resistance—difficulty getting approvals, publishing studies, and even testifying to a congressional hearing. She argues that when corporate and regulatory interests become entangled, the integrity of science suffers, independent investigators are silenced or sidelined, and public trust erodes. GET SOCIAL WITH US!

Pharma giant Eli Lilly manufactures the ingredients for its weight-loss drug Mounjaro and its diabetes drug Zepbound in Kinsale, Co Cork.The Irish Fiscal Advisory Council (Ifac) has found that the unprecedented surge in Irish exports this year (exports to the US rose by 153 per cent to €71bn between January and May) was almost entirely driven by shipments of these ingredients.Ifac tracked about €36.4bn of this export surge to Indianapolis, where Eli Lilly is headquartered and where it has several manufacturing sites.The jump in exports is expected to see the Irish economy expand by almost 11 per cent in GDP terms this year, which is almost certain to make it the fastest-growing advanced economy in the world in 2025.So with such an over-reliance on foreign direct investment, notably in the pharma sector, at a time of tariff threats and uncertainty, how vulnerable is Ireland?Irish Times economics correspondent Eoin Burke-Kennedy explains.Presented by Bernice Harrison. Produced by Suzanne Brennan and Andrew McNair. Hosted on Acast. See acast.com/privacy for more information.

Modified shipping containers are transforming pharmaceutical cold chain logistics with scalable, mobile, and temperature-controlled solutions. Discover the technology keeping medicines safe from production to patient. Read more at https://www.conexwest.com/cold-storage-and-freezers-sale/40ft-insulated-shipping-container Conexwest City: Lathrop Address: 17100 S Harlan Rd Website: https://www.conexwest.com/

Jordan Sather and Nate Prince deliver a packed episode of MAHA News, kicking off with the CDC's explosive website update acknowledging that claims of “no link” between vaccines and autism are not evidence-based, triggering absolute meltdown across legacy media, pharma loyalists, and blue-state health bureaucracies. The hosts track the political fallout, RFK Jr.'s direct role in ordering the change, and the wave of scientists now admitting long-ignored biologic mechanisms worth investigating. From Bhattacharya and Makary's blunt critiques of captured institutions to Robert Malone exposing the financial corruption inside the AAP and ACIP, the guys highlight a medical landscape finally cracking open. Jordan and Nate also dive into SSRIs, microbiome destruction, gut health, antibiotic overuse, and the soaring chronic-illness rates no one in the old regime wants to talk about. The episode closes with a fiery breakdown of SNAP as corporate welfare, revealing how billions in taxpayer dollars funnel straight into Coca-Cola, Frito-Lay, Walmart, and Big Food, while politicians pretend it's about “feeding the poor.” A fast, funny, and fiercely honest episode charting the scientific and political shifts reshaping U.S. health policy.

P.M. Edition for Nov. 21. It's mostly tech companies that have hit the milestone of a $1 trillion valuation. As WSJ Heard on the Street columnist David Wainer explains, Eli Lilly's entrance into this elite club is for a completely different reason: weight-loss drugs. Plus, New Mexico is one of the poorest states in the U.S., but it's planning to spend millions of dollars per year to be the first state to offer universal childcare. We hear from WSJ economics reporter Harriet Torry about how the plan will work, and what critics say. And now that the U.S. has presented its 28-point peace plan to Ukraine, President Trump says he expects an answer by Thanksgiving, leaving Ukrainian President Volodymyr Zelensky with what he calls a very difficult choice. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Ever notice how Pharma companies seem to be making more cosmetic drugs and backing away from curing diseases? I discuss this with Dr. Shoshana Shendelman. More open phones and conversations follow.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by significant scientific advancements, regulatory approvals, and strategic shifts that are reshaping the industry.Starting with Regeneron, the company's ophthalmic drug Eylea HD has recently secured two FDA approvals. These endorsements not only grant a new indication but also introduce a more flexible dosing regimen. This positions Eylea HD competitively against Roche's Vabysmo, highlighting the importance of regulatory navigation and strategic positioning in the pharmaceutical sector. These approvals come after extensive negotiations with both the FDA and third-party manufacturers, emphasizing the intricate processes involved in bringing a drug to market.In oncology, Bayer has achieved an accelerated FDA approval for Hyrnuo, a treatment targeting HER2-mutated non-small cell lung cancer. This move allows Bayer to challenge Boehringer Ingelheim's Hernexeos, underscoring the fiercely competitive nature of the oncology market. Such advancements are driven by innovative treatments that address specific genetic mutations in cancer patients, reflecting a broader trend towards precision medicine.Meanwhile, Moderna is investing heavily in mRNA production capabilities with a new $140 million facility in Norwood, Massachusetts. This development underscores Moderna's commitment to mRNA technology, which gained significant attention during the COVID-19 pandemic. The facility aims to establish robust domestic manufacturing infrastructures to mitigate supply chain vulnerabilities—a critical move considering recent global disruptions.Novartis is also making headlines with its plans for a flagship production hub in North Carolina. This expansion is expected to create 700 jobs and expand its manufacturing footprint by 700,000 square feet, highlighting Novartis's strategic emphasis on scaling up operations to meet growing demands and enhance production efficiency.In another strategic collaboration, Antheia has joined forces with Teva's TAPI division to enhance the commercialization prospects for its biosynthetic pipeline. This alliance marks a significant step toward advancing biologically derived pharmaceuticals, promising to revolutionize drug production through more sustainable and scalable alternatives to traditional chemical synthesis.On the regulatory front, Merck has received broad EU approval for a subcutaneous formulation of Keytruda. This development could significantly expand Keytruda's market reach across Europe, demonstrating how regulatory agility can extend drug lifecycles and maximize therapeutic impact across diverse patient populations.Compliance challenges remain prevalent, as illustrated by Pfizer and Tris Pharma's settlement of allegations related to ADHD medication Quillivant's quality control issues for $41.5 million. This case highlights ongoing efforts to ensure stringent quality standards within pharmaceutical manufacturing processes.Abbott is expanding its diagnostics portfolio through a $23 billion acquisition of Exact Sciences, known for its Cologuard colorectal cancer test. This acquisition indicates a strategic shift towards enhancing diagnostic capabilities alongside therapeutic offerings—a trend increasingly evident in holistic healthcare solutions.GSK is embarking on a $7 billion collaboration with biotechs Quotient and Profound through Flagship Pioneering. This partnership aims to leverage novel protein and genomic technologies to drive innovation in drug discovery and development, illustrating the industry's focus on integrating advanced biotechnological insights into traditional pharmaceutical frameworks.These developments collectively underscore crSupport the show

Wingman Epstein - 11.19.2025 - #893 BestPodcastintheMetaverse.com Canary Cry News Talk #893 - 11.19.2025 - Recorded Live to 1s and 0s Deconstructing World Events from a Biblical Worldview Declaring Jesus as Lord amidst the Fifth Generation War! CageRattlerCoffee.com SD/TC email Ike for discount https://CanaryCry.Support   Send address and shirt size updates to canarycrysupplydrop@gmail.com   Join the Canary Cry Roundtable This Episode was Produced By:   Executive Producers LX Protocol BARON of the Berrean Protocol*** Trevor G*** Felicia D***   Producers of TREASURE (CanaryCry.Support) Jeremy M, Monica, Cage Rattler Coffee   Producers of TIME Timestampers: Jade Bouncerson, Morgan E Clankoniphius Links: JAM   EPSTEIN "Almost" Unanimous Vote to release Epstein files (NBC) Sttacey Plaskett was "Coached by epstien during Cohen Hearing. (NYT) Clip: Jamie "Defends" Plaskett saying "Theres a lot more to come out"  Clip: Larry summers apologizes for epstein connection in his college class Epstein was Larry Summers' "Wingman" (INDY)   PHARMA The Rise and Fall of "Osterich Pharma" (The Aatlantic)    POLYTICKS Forget Joe Rogan. The Next Big Podcast Bro Is in the Senate. (Politico)   EXECUTIVE PRODUCERS TALENT/TIME END

Dr. Rachel Gatlin entered neuroscience with curiosity and optimism. Then came chaos. She started her PhD at the University of Utah in March 2020—right as the world shut down. Her lab barely existed. Her advisor was on leave. Her project focused on isolation stress in mice, and then every human on earth became her control group. Rachel fought through supply shortages, grant freezes, and the brutal postdoc job market that treats scientists like disposable parts. When her first offer vanished under a hiring freeze, she doubled down, rewrote her plan, and won her own NIH training grant. Her story is about survival in the most literal sense—how to keep your brain intact when the system built to train you keeps collapsing.RELATED LINKS• Dr. Rachel Gatlin on LinkedIn• Dr. Gatlin's Paper Preprint• Dr. Eric Nestler on Wikipedia• News Coverage: Class of 2025 – PhD Students Redefine PrioritiesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the intricate tapestry of scientific advancements, regulatory decisions, and strategic maneuvers shaping our industry.One of the notable stories involves Agios Pharmaceuticals, which is pushing forward with its sickle cell disease treatment, Pyrukynd, for FDA approval. This comes despite mixed results from their Phase 3 clinical trials, which led to a significant drop in their stock value. This scenario underscores the complexities of navigating clinical trial outcomes while pursuing breakthroughs in treating challenging diseases like sickle cell.Arrowhead Pharmaceuticals has marked a significant milestone with the FDA's approval of Plozasiran. This achievement not only marks Arrowhead's entry into the commercial sector but also highlights the competitive dynamics within biotech, as companies like Ionis Pharmaceuticals vie for market dominance with innovative therapies. Further strengthening its position, Arrowhead also received FDA approval for Redemplo, a siRNA-based therapeutic for rare genetic metabolic disorders. Despite facing volatility due to safety concerns in its partnership with Sarepta Therapeutics, this approval underscores RNA interference therapies' potential in precision medicine.In corporate strategy news, Alkermes is making moves to acquire Avadel Pharmaceuticals, offering up to $2.37 billion and overshadowing a competing bid from Lundbeck. Such acquisitions are part of a broader trend of consolidation in the industry aimed at expanding portfolios and market reach. Avadel's decision to accept Alkermes' revised offer over Lundbeck's bid highlights ongoing consolidation trends as companies expand their portfolios in competitive markets like narcolepsy drugs.On the investment front, Celltrion has committed $478 million to upgrade a U.S. manufacturing facility acquired from Eli Lilly. This expansion is crucial for increasing manufacturing capabilities within the biosimilars sector, where demand for cost-effective therapeutics is on the rise. Additionally, Celltrion's exploration beyond biosimilars with a potential $350 million deal involving Trioar's antibody platform demonstrates ambition to diversify its portfolio towards innovative biologics.Teva Pharmaceuticals is fostering innovation by inviting startups to tackle key challenges within biopharma through a global platform. This initiative reflects a growing trend toward open innovation and collaboration, seeking novel solutions to complex issues across research and development and manufacturing efficiencies.In regulatory news, the controversial $7.4 billion settlement plan involving the Sackler family and Purdue Pharma has received approval from a bankruptcy judge. This paves the way for Purdue's transformation into Knoa Pharma and highlights ongoing legal and ethical reckonings related to opioid liabilities within the industry.Cytokinetics remains committed to its independent path as it awaits FDA approval for its cardiovascular drug Aficamtem. The company's determination to commercialize without big pharma support reflects a trend where smaller biotech firms strive for autonomy while bringing first-in-class drugs to market.On an infectious disease front, Merck has demonstrated significant progress with its HIV treatment Islatravir in Phase 3 trials. This places Islatravir as a potential competitor against Gilead's Biktarvy, showcasing ongoing innovation within antiviral drug development.Additionally, Dexcom has gained clearance for its type 2 diabetes software integrating continuous glucose monitoring technology. This advancement exemplifies how digital health technologies are transforming chronic disease management bySupport the show

In this episode of the Medical Sales Podcast, Samuel sits down with Jennifer Jones, a former top Purdue Pharma rep who lived through the rise, collapse, and aftermath of one of the most controversial chapters in pharmaceutical history. Jennifer opens up about her early passion for pain management, what reps were taught, how Q12 vs Q8 dosing shaped patient experiences, and the moment Purdue shut down while she was on vacation. She shares the emotional toll of grand jury testimony, FBI investigations, and watching once-trusted leaders face prison time, while also revealing the patients and physicians who were genuinely trying to do the right thing. From navigating "pill mill" stereotypes to seeing pain doctors wrongly targeted, Jennifer gives a raw, inside look at the complexities reps faced long before the media headlines. Now a thriving medical device rep in cardiology, she talks about rebuilding her career, stepping into entrepreneurship, and rediscovering her purpose in healthcare. This is one of the most honest conversations ever recorded about pharma, pain management, and what it means to survive, grow, and lead in medical sales.   Connect with Jennifer Jones: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How »

EPISODE DESCRIPTIONBefore she was raising millions to preserve fertility for cancer patients, Tracy Weiss was filming reenactments in her apartment for the Maury Povich Show using her grandmother's china. Her origin story includes Jerry Springer, cervical cancer, and a full-body allergic reaction to bullshit. Now, she's Executive Director of The Chick Mission, where she weaponizes sarcasm, spreadsheets, and the rage of every woman who's ever been told “you're fine” while actively bleeding out in a one-stall office bathroom.We get into all of it. The diagnosis. The misdiagnosis. The second opinion that saved her life. Why fertility preservation is still a luxury item. Why half of oncologists still don't mention it. And what it takes to turn permission to be pissed into a platform that actually pays for women's futures.This episode is blunt, hilarious, and very Jewish. There's chopped liver, Carrie Bradshaw slander, and more than one “fuck you” to the status quo. You've been warned.RELATED LINKSThe Chick MissionTracy Weiss on LinkedInFertility Preservation Interview (Dr. Aimee Podcast)Tracy's Story in Authority MagazineNBC DFW FeatureStork'd Podcast EpisodeNuDetroit ProfileChick Mission 2024 Gala RecapFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What's on your mind? Let CX Passport know...Curiosity from the lab. Creativity from marketing. Transformation across a global pharma giant. Trina Di Giusto brings a scientist's discipline and a storyteller's instinct to CX. She explains how decentralized teams can still create harmony, why AI is tempting but rarely the fix, and what it takes for change to stick in a complex organization.5 Insights From This Episode • Scientific thinking becomes a CX advantage… methodical meets imaginative • Pharma customers span patients, providers, payers, and regulators • Delegation without orchestration leads to fragmentation • AI only works when the underlying process is healthy • Real change lasts when vision, skills, incentives, resources, and action alignCHAPTERS 00:00 Meet Trina from Basel 01:27 When science meets storytelling 03:47 Logic in a creative world 05:50 Blurring science and marketing 08:29 Defining CX in pharma 11:18 Delegation versus orchestration 13:57 First Class Lounge 18:01 Why tech is not the fix 22:51 What change management really requires 25:56 Lessons across six transformation cycles 28:06 Final takeaways and how to reach TrinaGuest Links LinkedIn: https://www.linkedin.com/in/trinadigiusto/Listen, Watch, Newsletter Listen: https://www.cxpassport.com Watch: https://www.youtube.com/@cxpassport Newsletter: https://cxpassport.kit.com/signupI'm Rick Denton and I believe the best meals are served outside and require a passport.Disclaimer: This podcast is for informational and entertainment purposes only. The views and opinions expressed are those of the hosts and guests and should not be taken as legal, financial, or professional advice. Always consult with a qualified attorney, financial advisor, or other professional regarding your specific situation. The opinions expressed by guests are solely theirs and do not necessarily represent the views or positions of the host(s).

What if one decision could make or break your drug's success? Join Charles River's Sarah Gould as she unpacks the high-stakes, emotion-filled world of species selection—and why it's about so much more than science. Discover how this critical choice shapes safety, speeds development, and drives innovation in today's evolving research landscape.Show Notes Alternative Methods Advancement Project  | Charles River Animals in Research  | Charles River Research Models and Services | Charles River Research Animals Models | Charles River 

Drug discovery has doubled the flow of candidates, but approvals remain roughly flat. The constraint is development, not discovery. In this episode, a16z General Partner, Jorge Conde talks with Formation Bio cofounder and CEO Ben Liu about building a modern pharma company around clinical execution. They discuss Formation Bio's hub-and-spoke model for acquiring and advancing assets, how AI compresses trial timelines and costs, picking winners, regulatory strategy, and what it would take to move from about 50 approvals a year to many more. They also touch on global competition and why clinical proof still drives value in today's market. Timecodes: 0:00 Introduction0:38 Why Formation Bio? Origins and Mission1:12 The Real Bottleneck: Clinical Development4:56 Formation Bio's Business Model7:50 Picking Winners: The Art and Science of Drug Selection11:54 First-in-Class vs. Best-in-Class Strategies14:04 Overcoming Regulatory and Market Challenges17:26 The Stakes: Can We Approve More Drugs?19:07 How Formation Bio Cuts Cost and Time21:43 AI's Role in Drug Development25:10 The Future: From 50 to 500 Drug Approvals?35:18 Global Competition: The Rise of China39:28 The Path Forward: Data, Regulation, and Access41:47 Conclusion: Realizing the AI Revolution in Pharma Resources: Find Ben on X: https://x.com/BenjamineYLiuFind Jorge on X: https://x.com/JorgeCondeBio Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends!Find a16z on X: https://x.com/a16zFind a16z on LinkedIn: https://www.linkedin.com/company/a16zListen to the Raising Health Podcast on Spotify: https://open.spotify.com/show/4fjb8YTzHDuPBgDXc3ElkRListen to the Raising Health Podcast  Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/raising-health/id1529318900Follow our host: https://x.com/eriktorenbergPlease note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The best biotech and pharmaceutical innovations mean nothing if they can't be protected—and protected fast. Our next guest, Josh Goldberg, is solving this challenge as co-managing partner at Nath, Goldberg & Meyer, the #1 ranked patent law firm for biotech and pharmaceutical technologies. With nearly three decades of IP law experience and a unique background as a lab researcher, Josh brings an insider's understanding of how innovation actually happens. He's helped industry leaders like Amgen, Takeda, and GlaxoSmithKline turn breakthrough treatments into patent-protected portfolios—often in under a year instead of the typical four-year timeline. Driven by a passion for focus and strategic IP timing, Josh shares his pioneering approach to biotech and pharmaceutical patent prosecution. Join us to discover how smart IP strategy drives licensing power, regulatory success, and company valuation. Let's go!Episode Highlights:Focus drives success – Companies fail by trying to do everything at once; staying deliberate and focused is key to making real impactOne-year patent timelines vs. four years – Josh uses USPTO's Track 1 program to secure patents in record time, improving fundraising and M&A positioningClient-centered approach wins – Listening to unique client needs instead of one-size-fits-all strategies earned the firm its #1 rankingDiagnostic patents are back – New USPTO Director signals the patent office is "open for business" again after a decade of restrictionsScientist turned patent attorney – Josh's lab background gives him insider understanding of how innovation actually happensAbout our Guest: Joshua is the patent attorney innovation-driven pharmaceutical companies call when they need to turn complicated technologies into protected assets in record time.As co-managing partner at Nath, Goldberg & Meyer—the #1 ranked patent law firm for biotech and pharmaceutical technologies in both 2024 and 2025—Joshua leads IP efforts across industries like biotech, pharma, agriculture, renewable energy, and advanced materials. Whether it's a blockbuster acne treatment like DUAC, a vitamin D analog lotion like Sorilux, OTC solutions like Salonpas and Germagic, or a leading drug used to reduce stomach acid and treat conditions like GERD, ulcers, and heartburn—like Protonix—Joshua helps turn high-stakes R&D into patent-protected portfolios, often in under a year instead of the typical four-year timeline.Though his climate and agricultre IP expertise has made him famous as the “green patent guy,” Joshua moves between disciplines skillfully and has helped industry leaders like Amgen, Takeda, Guilford Pharmaceuticals, Mayne, and Stiefel Laboratories (which was acquired by GlaxoSmithKline) build pharma portfolios that hold up under investor, acquirer, and FDA scrutiny.His journey didn't begin in IP law, but in the lab, researching experimental pharmaceutical delivery systems. It gave him an edge most attorneys don't have: understanding how innovation actually happens, and how to protect it without slowing a business down. Links Supporting This Episode: Nath, Goldberg & Meyer Website: CLICK HEREJoshua Goldberg LinkedIn page: CLICK HERENath, Goldberg & Meyer LinkedIn: CLICK HEREMike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page:...

Do you have a medical sales interview coming up?Pharma, medical device, diagnostics, or biotech… this video will help you stand out and win the offer. This industry is highly competitive, and the candidates who succeed do more than answer questions. They own the interview. What you will learn in this episode: - How to make a powerful first impression with “Tell me about yourself”- How to walk through your resume like a top performer- How to connect your background to the company's mission, product, and impact on patients- How to communicate what makes you unique without clichés- How to discuss strengths and weaknesses with strategy and confidence- How to show cultural fit and real motivation- How to navigate the salary question without losing momentum- How to close strong and leave a memorable impressionEverything I teach comes from real hiring experience in medical sales, including pharma and oncology. After this video, you will know exactly how to prepare with purpose, communicate like a professional, and outperform people who may have more experience on paper.If you are serious about getting into or advancing in medical sales, you are in the right place.Subscribe to get coaching, tools, and real interview strategies that help you win the offer.Preparation creates confidence. Confidence wins offers.Learn more about coaching and career support at https://medicalsalesu.com/

Send Zorba a message!ProPublica (an independent, non-profit news organization) recently reported on the FDA's handling of potential safety issues concerning generic drugs we get from overseas manufacturers. Some of their findings include:·     For decades, the FDA has blacked out the names of generic drugs on inspection reports for foreign factories that were found to have safety and quality violations. ·     This has prevented patients, doctors, and pharmacists from knowing whether manufacturing failures have made medications ineffective or unsafe. You can find the ProPublica article here(Recorded Nov 10, 2025)Support the showProduction, edit, and music by Karl Christenson Send your question to Dr. Zorba (he loves to help!): Phone: 608-492-9292 (call anytime) Email: askdoctorzorba@gmail.com Web: www.doctorzorba.org Stay well!

In this episode of Molecule to Market, your host Raman Sehgal discusses the pharmaceutical and biotechnology supply chain with Jean-François Brepson, Chief Executive Officer at PathoQuest. The conversation covers: Navigating 20 years of global leadership roles at Ipsen before moving from the corporate world into an investor-led entrepreneurial adventure The tough decision to refocus PathoQuest from diagnostics into a pure play CRO and pharma services business How a major strategic partnership transformed the company's trajectory and why Jean sees partnerships as a competitive weapon Riding the tailwind of the FDA's move away from animal testing and offering something game-changing in the CMC and GMP space The opportunities ahead for CROs and CDMOs in helping unlock the next wave of innovation Jean-François Brepson is a dedicated leader with deep experience in biotechnology and pharmaceuticals. Since becoming CEO of PathoQuest in 2015, he has built the company into a leading global CRO specializing in quality control of biological drugs using Next Generation Sequencing (NGS). Over his career, he has advanced innovative technologies and solutions that bridge scientific progress with real-world application. Prior to joining PathoQuest, Jean was Senior Vice President at Ipsen, where he led the global GI-Oncology and Endocrinology franchise.   Molecule to Market is sponsored by Bora Pharma, Charles River, and Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We'd also appreciate a positive rating!

Angel Studios https://Angel.com/HermanJoin the Angel Guild today and know you are not just watching, you're helping make bold, faith driven stories like Disciples in the Moonlight possible. That's Angel.com/HermanRenue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comRegister now for the free Review/Preview Webinar November 20th 3:30pm Pacific, schedule your free Know Your Risk Portfolio Review, and subscribe to Zach's Daily Market Recap at (SLOW) Know Your Risk Podcast dot com. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/toddThe new GOLDEN AGE is here!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.The ultimate unholy union is government and healthcare. President Trump has put out some words on government and healthcare, and President Trump, is a good friend of big Pharma.Episode Links:Democrat Senator Peter Welch on Obamacare: "We did fail to bring down the cost of healthcare."American doctor goes over how Barack Obama destroyed American HealthcareObamacare is only 7% of Americans. Literally almost 100% of Americans need relief from their health care policy premiums, not just 7%. We need to have free market solutions that bring down the cost of health care for every American, not just the 7%.The Danish Cow Crisis: Bill Gates, “Bovaer,” and the War on Nature. In Denmark, farmers are raising alarms after a new climate-driven feed additive called Bovaer became mandatory on October 1, 2025.Virtually everything that Obama promised about Obamacare was a lie. Now the country is stuck dealing with the ramifications. Instead of taking responsibility, Democrats have shut down the government and are demanding that Republicans fix what they broke.

Canadian journalist Nora Loreto reads the latest headlines for Wednesday, November 12, 2025.TRNN has partnered with Loreto to syndicate and share her daily news digest with our audience. Tune in every morning to the TRNN podcast feed to hear the latest important news stories from Canada and worldwide.Find more headlines from Nora at Sandy & Nora Talk Politics podcast feed.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-news-podcast--2952221/support.Help us continue producing radically independent news and in-depth analysis by following us and becoming a monthly sustainer.Follow us on:Bluesky: @therealnews.comFacebook: The Real News NetworkTwitter: @TheRealNewsYouTube: @therealnewsInstagram: @therealnewsnetworkBecome a member and join the Supporters Club for The Real News Podcast today!

In search of the next miracle “cure,” Big Pharma has become very proficient at developing highly effective and obscenely profitable drugs aimed at treating rare diseases (think $750,000 per year) at the expense of ignoring newer, safer and effective treatments geared to a wider audience.Alex Martinez, CEO and cofounder of Intrinsic Medicine, shares his amazing journey from being a healthcare attorney who witnessed the good, bad and mostly ugly in Big Pharma to revolutionizing how we care for the human microbiome this week on Spirit Gym. Learn more about Alex's Intrinsic Medicine company at his website. Find him on social media via LinkedIn.Show Notes8:47 “The mission was attractive to me.”12:27 Alex got the education he needed while ground-truthing at the same time.20:50 Why is Big Pharma's disproportionate focus on drugs that treat rare diseases?30:16 Evolutionary biology.39:07 Alex is a very intelligent vegetable.44:42 Human milk oligosaccharides (HMOs) formulated with information molecules.51:53 The fecal transplant isn't new science.1:06:46 Freediving helped Alex look inward toward the microbiome.1:13:26 “What's inside of us is all around us.”1:25:05 The HMOs in breast milk serve as training mechanisms in a baby's gut.1:36:05 Is it possible that HMOs could work one day like fecal transplants?1:44:47 Where do these HMOs originate?1:50:33 Formulating infant formulas that aren't inflammatory should be the norm but aren't.2:07:29 Creating an ethical regenerative business by integrating humanity into it.2:12:49 Humans are so good at finding comfort in dis-ease.2:25:34 Where probiotics went wrong.Resources BifidobacteriumFructooligosaccharides (FOS)Paul's Living 4D conversation with Dr. Nathan RileyThe Abdominal and Pelvic Brain by Byron RobinsonFind more resources for this episode on our website.Music Credit: Meet Your Heroes (444Hz), Composed, mixed, mastered and produced by Michael RB Schwartz of Brave Bear MusicThanks to our awesome sponsors:PaleovalleyBIOptimizers US and BIOptimizers UK PAUL15Organifi CHEK20Wild PasturesKorrect SPIRITGYMPique LifeCHEK Institute We may earn commissions from qualifying purchases using affiliate links.

EPISODE DESCRIPTION:Libby Amber Shayo didn't just survive the pandemic—she branded it. Armed with a bun, a New York accent, and enough generational trauma to sell out a two-drink-minimum crowd, she turned her Jewish mom impressions into the viral sensation known as Sheryl Cohen. What started as one-off TikToks became a career in full technicolor: stand-up, sketch, podcasting, and Jewish community building.We covered everything. Jew camp lore. COVID courtship. Hannah Montana. Holocaust comedy. Dating app postmortems. And the raw, relentless grief that comes with being Jewish online in 2025. Libby's alter ego lets her say the quiet parts out loud, but the real Libby? She's got receipts, range, and a righteous sense of purpose.If you're burnt out on algorithm-friendly “influencers,” meet a creator who actually stands for something. She doesn't flinch. She doesn't filter. And she damn well earned her platform.This is the most Jewish episode I've ever recorded. And yes, there will be guilt.RELATED LINKSLibby's Website: https://libbyambershayo.comInstagram: https://www.instagram.com/libbyambershayoTikTok: https://www.tiktok.com/@libbyambershayoLinkedIn: https://www.linkedin.com/in/libby-walkerSchmuckboys Podcast: https://jewishjournal.com/podcasts/schmuckboysForbes Feature: Modern Mrs. Maisel Vibes https://www.forbes.com/sites/joshweissMedium Profile: https://medium.com/@libbyambershayoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform.For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Pharma is toxic and supplements are natural, right? Let's take a closer look. Get Take Daily HERE. LINKS AND RESOURCES: Watch Video Version Here: Rumble Video Bitchute Video Youtube Video-...

- Brighteon Broadcast News Introduction and AI Revolution Interview (0:10) - Collapse of Human Doctors and Pharmaceutical Industry (1:51) - Trump's Announcement and AI Replacements (11:06) - Economic Collapse and AI Solutions (12:06) - Replacing Congress with AI Agents (34:46) - AI Capabilities and Public Perception (52:28) - The Future of AI and Human Knowledge (1:23:58) - Psychological Barriers and Humility in AI Interaction (1:25:23) - The Future of the Book Industry (1:28:17) - Customization and Personalization in AI (1:35:16) - Advancements in AI and Human Cognition (1:36:27) - Investing in Personal Growth and Skills (1:40:16) - Decentralization and Privacy in AI (1:48:27) - The Role of AI in Personal and Professional Development (1:57:17) - The Future of AI and Robotics (2:07:23) - The Global Race in AI and Technological Advancements (2:10:21) - The Impact of AI on Employment and Society (2:18:24) For more updates, visit: http://www.brighteon.com/channel/hrreport  NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

Today The Chicks talk about everything from a Big Pharma exec collapsing during Trump's presser in the Oval Office to Kennedy's bold plan to cut Congress's pay during a shutdown. Meanwhile, Pelosi's retirement, Rand Paul's defiance, and MTG's throwbacks bring the heat.Plus: Tucker's Fuentes backlash, Islam's spread across Texas and NYC, and Gen Z's disturbing defense of socialist Rep. Mamdani. This episode covers all the insanity — from “fat privilege” to fake ICE stories, liberal TikTok meltdowns, and a viral reporter trying to shame Sydney Sweeney.SUPPORT OUR SPONSORS TO SUPPORT OUR SHOW!Become a premium member of the Angel Guild at https://Angel.com/Chicks to stream YoungDavid today and get two free tickets to see David in theaters this Christmas.Take advantage of Prolon's limited-time offer—get 15% off sitewide plus a $40 bonus gift whenyou subscribe to their 5-Day Program at https://Prolonlife.com/CHICKSNourish your hair, skin, and nails with HealthyCell's Vibrant Hair, Skin & Nails—get 20% off your first order at https://HealthyCell.com/CHICKS with promo code CHICKS.Whatever fall throws at you, make sure you're prepared—visit https://ReadyWise.com and use codeCHICKS10 for 10% off your order today!